4.7 Review

Cell-free circulating tumour DNA as a liquid biopsy in breast cancer

期刊

MOLECULAR ONCOLOGY
卷 10, 期 3, 页码 464-474

出版社

WILEY
DOI: 10.1016/j.molonc.2015.12.001

关键词

Breast cancer; Circulating cell-free tumour DNA; Stratification; Monitoring; Resistance; Heterogeneity

类别

资金

  1. Cancer Research UK [16942] Funding Source: researchfish
  2. National Institute for Health Research [NF-SI-0515-10090, NF-SI-0611-10154] Funding Source: researchfish

向作者/读者索取更多资源

Recent developments in massively parallel sequencing and digital genomic techniques support the clinical validity of cell-free circulating tumour DNA (ctDNA) as a 'liquid biopsy' in human cancer. In breast cancer, ctDNA detected in plasma can be used to non invasively scan tumour genomes and quantify tumour burden. The applications for ctDNA in plasma include identifying actionable genomic alterations, monitoring treatment responses, unravelling therapeutic resistance, and potentially detecting disease progression before clinical and radiological confirmation. ctDNA may be used to characterise tumour heterogeneity and metastasis-specific mutations providing information to adapt the therapeutic management of patients. In this article, we review the current status of ctDNA as a `liquid biopsy' in breast cancer. (C) 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据